Isbn: 9783540278672 - appropriate dose selection - how to optimize clinical drug development: 59 (ernst schering foundation symposium proceedings, 59) (8 resultados)

Condición: Brand New. New. US edition. Expediting shipping for all USA and Europe orders excluding PO Box. Excellent Customer Service.

Condición: Gut. Zustand: Gut | Sprache: Englisch | Produktart: Bücher | Optimal dose individualization has become more important in improving clinical efficacy and safety, given the variability in drug response, e.g., due to concurrent illnesses or co-medications. Therefore, the role of optimal dose finding in early clinical drug development so as to maximize successful clinical use is emphasized. The continued use of biomarkers ¿ based on the (known) pharmacology of the drug and/or biology of the underlying disease ¿ along with exposure¿response evaluation throughout all phases of drug development can quantitatively integrate clinical pharmacology knowledge, provide early proof of concept, and help in rational dose selection and rational drug product labeling for clinical use.…

Condición: Sehr gut. Zustand: Sehr gut | Sprache: Englisch | Produktart: Bücher | Optimal dose individualization has become more important in improving clinical efficacy and safety, given the variability in drug response, e.g., due to concurrent illnesses or co-medications. Therefore, the role of optimal dose finding in early clinical drug development so as to maximize successful clinical use is emphasized. The continued use of biomarkers ¿ based on the (known) pharmacology of the drug and/or biology of the underlying disease ¿ along with exposure¿response evaluation throughout all phases of drug development can quantitatively integrate clinical pharmacology knowledge, provide early proof of concept, and help in rational dose selection and rational drug product labeling for clinical use.…

Hardcover. Condición: gut. 2007. Appropriate Dose Selection - How to Optimize Clinical Drug Development (Ernst Schering Foundation Symposium Proceedings, 59, Band 59) In deutscher Sprache. pages.

Buch. Condición: Neu. Druck auf Anfrage Neuware - Printed after ordering - Optimal dose individualization has become more important in improving clinical efficacy and safety, given the variability in drug response, e.g., due to concurrent illnesses or co-medications. Therefore, the role of optimal dose finding in early clinical drug development so as to maximize successful clinical use is emphasized. The continued use of biomarkers - based on the (known) pharmacology of the drug and/or biology of the underlying disease - along with exposure-response evaluation throughout all phases of drug development can quantitatively integrate clinical pharmacology knowledge, provide early proof of concept, and help in rational dose selection and rational drug product labeling for clinical use.…

Condición: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Reviews innovative methods, tools and examples of rational drug development strategies, particularly for novel oncological agentsOptimal dose individualization has become more important in improving clinical efficacy and safety, given the variability.…

Buch. Condición: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Optimal dose individualization has become more important in improving clinical efficacy and safety. This is due in part to the variability in drug response. Therefore, the role of optimal dose finding in early clinical drug development so as to maximize successful clinical use is emphasized. This book reviews innovative methods, tools and examples of rational drug development strategies, particularly for novel oncological agents. 240 pp. Englisch.…

Buch. Condición: Neu. This item is printed on demand - Print on Demand Titel. Neuware -Optimal dose individualization has become more important in improving clinical efficacy and safety, given the variability in drug response, e.g., due to concurrent illnesses or co-medications. Therefore, the role of optimal dose finding in early clinical drug development so as to maximize successful clinical use is emphasized. The continued use of biomarkers ¿ based on the (known) pharmacology of the drug and/or biology of the underlying disease ¿ along with exposure¿response evaluation throughout all phases of drug development can quantitatively integrate clinical pharmacology knowledge, provide early proof of concept, and help in rational dose selection and rational drug product labeling for clinical use.Springer-Verlag KG, Sachsenplatz 4-6, 1201 Wien 240 pp. Englisch.…